Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results:
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following 4Q
January 23, 2020 6:39 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $168.00 price target on Johnson & Johnson (NYSE: JNJ) following the company's 4Q earnings report. Chen continues to believe that upward earnings revisions to JNJ's Pharma business and multiple expansion, driven by diminishing headlines... More
Johnson & Johnson (JNJ) Tops Q4 EPS by 1c, Offers FY20 Guidance
January 22, 2020 6:33 AM EST(Updated - January 22, 2020 6:33 AM EST)
Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.88, $0.01 better than the analyst estimate of $1.87. Revenue for the quarter came in at $20.7 billion versus the consensus estimate of $20.77 billion.
GUIDANCE:
Johnson & Johnson sees FY2020 EPS of... More
